Merck (MRK) Stock Analysis
Here is a fundamental analysis of Merck (MRK), benchmarking its profitability, financial strength, dividend and valuation against its industry group peers.
Performance
Cumulative Growth
Trailing Returns
Performance at a Glance
| Metric | Current stock: MRK | Industry group median |
|---|---|---|
| 1-Year Return | 50.79% | 44.56% |
Risk
Drawdown
Risk at a Glance
| Metric | Current stock: MRK | Industry group median |
|---|---|---|
| 1-Year Volatility | 27.18% | 67.11% |
| Beta | 0.20 | 0.93 |
Company Profile
| Profile Item | MRK |
|---|---|
| Name | Merck & Co., Inc. |
| Country/Region | United States |
| GICS Sector | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals |
| Market Capitalization | 294.03 billion USD |
| Currency | USD |
| Exchange | NYSE |
| Listing Date | January 2, 1962 |
| Security Type | Common Stock |
Valuation
Price-to-Earnings Ratio (TTM)
Merck (MRK) trades at P/E ratio of 33.54, near the industry’s usual earnings multiple. The stock is not showing a clear peer discount or premium on trailing earnings.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.54
Group distribution
- Max
- 77.14
- Q3
- 43.78
- MRK
- 33.54
- Median
- 24.68
- Q1
- 15.27
- Min
- 1.70
Largest peers
- ABBV
- 111.09
- LLY
- 40.32
- MRK
- 33.54
- JNJ
- 27.94
- AZN
- 26.96
- NVS
- 21.93
- NVO
- 10.30
Price-to-Sales Ratio (TTM)
Merck (MRK) trades at 4.47 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.47
Group distribution
- Max
- 55.38
- Q3
- 24.42
- Median
- 6.98
- MRK
- 4.47
- Q1
- 3.30
- Min
- 0.01
Largest peers
- LLY
- 13.98
- ABBV
- 6.40
- JNJ
- 6.02
- NVS
- 5.16
- AZN
- 4.59
- MRK
- 4.47
- NVO
- 0.59
Price-to-Book Ratio (MRQ)
Merck (MRK) trades at 6.41 on P/B ratio, in the higher book-value quartile. The market is paying a premium to book, so stronger ROE, cleaner assets, or a better growth profile need to justify it.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.41
Group distribution
- Max
- 13.23
- MRK
- 6.41
- Q3
- 6.38
- Median
- 3.46
- Q1
- 1.64
- Min
- -5.17
Largest peers
- LLY
- 32.45
- NVS
- 7.58
- JNJ
- 7.14
- MRK
- 6.41
- NVO
- 6.22
- AZN
- 5.85
- ABBV
- -60.45
Valuation at a Glance
| Metric | Current stock: MRK | Industry group median |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 33.54 | 24.68 |
| Price-to-Sales Ratio (TTM) | 4.47 | 6.98 |
| Price-to-Book Ratio (MRQ) | 6.41 | 3.46 |
| Free Cash Flow Yield | 4.78% | -2.37% |
Profitability
Return on Equity (TTM)
Merck (MRK) posts ROE of 18.94%, in the upper peer quartile. That suggests the company earns more from each dollar of shareholders’ equity than most industry peers, a useful capital-efficiency signal.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.94%
Group distribution
- Max
- 101.32%
- MRK
- 18.94%
- Q3
- 2.92%
- Median
- -31.26%
- Q1
- -62.68%
- Min
- -158.89%
Largest peers
- LLY
- 107.46%
- NVO
- 71.40%
- NVS
- 34.93%
- JNJ
- 26.42%
- AZN
- 23.48%
- MRK
- 18.94%
- ABBV
- --
Net Profit Margin (TTM)
Merck (MRK) keeps 13.59% of revenue as net profit on net margin, above the industry benchmark range. That is unusually strong bottom-line conversion, though tax effects, asset sales, or other one-off gains should be checked before treating it as durable.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.59%
Group distribution
- MRK
- 13.59%
- Max
- 12.76%
- Q3
- 4.00%
- Median
- 0.00%
- Q1
- -2.26%
- Min
- -11.53%
Largest peers
- NVO
- 37.21%
- LLY
- 34.99%
- NVS
- 23.92%
- JNJ
- 21.83%
- AZN
- 17.19%
- MRK
- 13.59%
- ABBV
- 5.79%
Operating Profit Margin (TTM)
Merck (MRK) turns 38.60% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
38.60%
Group distribution
- Max
- 100.30%
- MRK
- 38.60%
- Q3
- 4.40%
- Median
- 0.00%
- Q1
- -131.52%
- Min
- -333.43%
Largest peers
- NVO
- 61.57%
- LLY
- 49.39%
- MRK
- 38.60%
- ABBV
- 32.16%
- NVS
- 30.48%
- AZN
- 27.94%
- JNJ
- 27.41%
Profitability at a Glance
| Metric | Current stock: MRK | Industry group median |
|---|---|---|
| Return on Equity (TTM) | 18.94% | -31.26% |
| Return on Assets (TTM) | 12.58% | -14.70% |
| Net Profit Margin (TTM) | 13.59% | 0.00% |
| Operating Profit Margin (TTM) | 38.60% | 0.00% |
| Gross Profit Margin (TTM) | 76.73% | 33.58% |
Financial Strength
Current Ratio (MRQ)
Merck (MRK) has current ratio of 1.30, in the tighter-liquidity quartile for its industry. The short-term cushion is thinner than most peers carry, even if the absolute comfort level still depends on the business model.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.30
Group distribution
- Max
- 24.81
- Q3
- 11.75
- Median
- 5.57
- Q1
- 2.69
- MRK
- 1.30
- Min
- 0.23
Largest peers
- LLY
- 1.50
- MRK
- 1.30
- JNJ
- 1.03
- AZN
- 0.91
- NVS
- 0.85
- ABBV
- 0.80
- NVO
- 0.79
Debt-to-Equity Ratio (MRQ)
Merck (MRK) has debt-to-equity ratio of 1.07, in the higher-leverage quartile for its industry. The heavier reliance on borrowing can make earnings, rates, or refinancing conditions matter more.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.07
Group distribution
- Max
- 1.60
- MRK
- 1.07
- Q3
- 0.68
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Largest peers
- LLY
- 1.39
- NVS
- 1.21
- MRK
- 1.07
- NVO
- 0.72
- AZN
- 0.72
- JNJ
- 0.68
- ABBV
- --
Financial Strength at a Glance
| Metric | Current stock: MRK | Industry group median |
|---|---|---|
| Current Ratio (MRQ) | 1.30 | 5.57 |
| Debt-to-Equity Ratio (MRQ) | 1.07 | 0.15 |
| Net Debt / EBITDA | 1.47 | 1.09 |
Dividends
Dividend Yield (TTM)
Merck (MRK) has dividend yield of 2.86%, above the entire industry range. That headline income is large, but yields this far above peers often come from a falling share price or an at-risk payout, so dividend safety matters more than the percentage itself.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.86%
Group distribution
- MRK
- 2.86%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- NVO
- 4.11%
- NVS
- 3.10%
- ABBV
- 3.04%
- MRK
- 2.86%
- JNJ
- 2.23%
- AZN
- 1.77%
- LLY
- 0.61%
Dividend Payout Ratio (TTM)
Merck (MRK) has payout ratio of 93.52%, above the peer distribution for its industry. The dividend consumes more reported earnings than peers normally do, leaving unusually thin earnings cover.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
93.52%
Group distribution
- MRK
- 93.52%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- ABBV
- 325.98%
- MRK
- 93.52%
- NVS
- 67.91%
- JNJ
- 60.25%
- AZN
- 47.70%
- NVO
- 42.59%
- LLY
- 22.13%
Dividends at a Glance
| Metric | Current stock: MRK | Industry group median |
|---|---|---|
| Dividend Yield (TTM) | 2.86% | 0.00% |
| Dividend Payout Ratio (TTM) | 93.52% | 0.00% |